Answers are grounded in this paper and cite their sources.
Investigates Regnase-1's impact on Treg function in vivo, indicating its essential regulatory role.
Regnase-1 is a CCCH-type RNA-binding protein that constantly degrades mRNA species via its ribonuclease domain to maintain immune quiescence. But how and by what mechanisms Regnase-1 regulates Foxp3 + Tregs remains poorly studied. Here, we generated a conditional knock-in strain in which a degradation-resistant Regnase-1 mutant (R111A) was selectively expressed in Foxp3 + Tregs as a transgene ( Foxp3 YFP-Cre LSL-R111A fl/fl ) to investigate the roles of Regnase-1 in Tregs. We found that all male Foxp3 YFP-Cre LSL-R111A fl/fl mice died of fatal autoimmune diseases by 4 weeks of age, which was accompanied by massive activation of T effector cells in vivo. We also found that the Foxp3 + Tregs in male Foxp3 YFP-Cre LSL-R111A fl/fl mice were progressively depleted in the periphery. Further analyses showed that the Foxp3 + Tregs expressing the R111A mutant displayed an intrinsic survival defect and that wild-type Foxp3 + Tregs adoptively transferred into young Foxp3 YFP-Cre LSL-R111A fl/fl mice could rescue the lethal autoimmune phenotype. Mechanistically, we demonstrated that the Regnase-1 readily degraded Bcl2l1 mRNA (encoding Bcl-xL) via binding to the Bcl2l1 mRNA stem loop structure, thus preventing Bcl-xL expression in Tregs. Thus, Tregs expressing the R111A mutant exhibited not only survival defects but also failure to respond to IL-2, resulting in their eventual demise in vivo. Together, our studies suggest that Regnase-1 can have a profound impact on Foxp3 + Tregs and that modulating Regnase-1 in Tregs may have important therapeutic implications.
No takes yet. Share an insight, caveat, or question.
Su et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: